EBS Stock Analysis: Buy, Sell, or Hold?
EBS - Emergent Biosolutions, Inc.
$7.41
0.19 (2.63%)
▲
5d:
+1.09%
30d:
-10.51%
90d:
-12.51%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
1d
Get Alerted When EBS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: EBS shows positive signals but monitor for confirmation. Market pricing in 15.2% decline. Moderate conviction.
💡 BUY OPPORTUNITY: EBS shows positive signals but monitor for confirmation. Market pricing in 15.2% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$12.11
Based on -0.1% avg growth
INTRINSIC VALUE TODAY
$7.52
1.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EBS is currently trading at $7.41, which is considered slightly low relative to its 30-day fair value range of $7.40 to $8.23. From a valuation perspective, the stock is trading at a discount (Forward PE: 8.1) compared to its historical average (13.4). Remarkably, the market is currently pricing in an annual earnings decline of 15.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EBS is in a downtrend. Immediate support is located at $7.05, while resistance sits at $7.73.
Market Sentiment: EBS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.00 (+61.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EBS is in a downtrend. Immediate support is located at $7.05, while resistance sits at $7.73.
Market Sentiment: EBS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.00 (+61.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$7.40 -
$8.23
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 61.9% below Wall St target ($12.00)
Trading Range Analysis
30-Day Trading Range
$7.40 -
$8.23
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.91
(12.3%)
Support & Resistance Levels
Support Level
$7.05
Resistance Level
$7.73
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.14
Wall Street Target
$12.00
(+61.9%)
Revenue Growth (YoY)
-29.7%
Earnings Growth (YoY)
-93.8%
Profit Margin
-1.3%
Valuation Discount vs History
-15.2% cheaper
PE vs Historical
8.1 vs 13.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-15.2%
(market-implied from PE analysis)
1-Year Target
$6.67
(-10%)
2-Year Target
$6.00
(-19%)
3-Year Target
$5.40
(-27%)
3-Yr Target (if PE normalizes)
(PE: 8→13)
$8.89
(+20%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: -4.2%)
$16.58
(+124%)
Base:
(SPY PE: 8.1, Growth: -4.2%)
$6.51
(-12%)
Bear:
(PE: 6.9, Growth: -4.2%)
$5.54
(-25%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.1 to 13.4
Stabilization Target:
$12.19
(+64.6%)
PE Expansion Potential:
+64.6%
Share & Embed Analysis
Last updated: August 03, 2026 6:34 PM ET
Data refreshes hourly during market hours. Next update: 7:34 PM
Data refreshes hourly during market hours. Next update: 7:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EBS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 52 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 45 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
Advanced EBS Option Strategies
Professional options setups generated by AI based on today's EBS price and gamma walls.
